QNCX · As filed with the SEC
Quince Therapeutics income statement, by fiscal year
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating expenses: | ||||||||
| Research and development | 35,382,000 | 18,590,000 | 9,447,000 | 25,178,000 | 60,795,000 | 61,307,000 | 30,214,000 | 10,085,000 |
| General and administrative | 15,047,000 | 17,580,000 | 17,695,000 | 26,012,000 | 29,523,000 | 17,586,000 | 8,954,000 | 2,034,000 |
| Goodwill impairment charge | — | — | — | 825,000 | — | — | — | — |
| Goodwill impairment charge | — | — | 0 | — | — | — | — | — |
| Goodwill impairment charge | 0 | 17,130,000 | — | — | — | — | — | — |
| Intangible asset impairment charge | — | 0 | 5,900 | — | — | — | — | — |
| Fair value adjustment for contingent consideration | — | 3,985 | 1,578 | — | — | — | — | — |
| Fair value adjustment for contingent consideration | 7,639,000 | — | — | — | — | — | — | — |
| Total operating expenses | 58,068,000 | 57,285,000 | 34,620,000 | 52,015,000 | 90,318,000 | 78,893,000 | 39,168,000 | 12,119,000 |
| Loss from operations | (58,068,000) | (57,285,000) | (34,620,000) | (52,015,000) | (90,318,000) | (78,893,000) | (39,168,000) | (12,119,000) |
| Interest income, net | — | — | — | — | — | — | 2,188,000 | 806,000 |
| Fair value adjustment for long-term debt | — | (1,709) | (338) | — | — | — | — | — |
| Fair value adjustment for debt | (2,043,000) | — | — | — | — | — | — | — |
| Fair value adjustment for warrants | (21,470,000) | — | — | — | — | — | — | — |
| Warrant issuance costs | (914,000) | — | — | — | — | — | — | — |
| Interest income | 1,244,000 | 2,929,000 | 3,478,000 | 1,068,000 | 620,000 | 2,044,000 | — | 806,000 |
| Interest expense | — | — | — | — | — | — | — | (957,000) |
| Change in fair value of derivative liability | — | — | — | — | — | — | — | (206,000) |
| Other income (expense), net | 486,000 | (676,000) | (102,000) | (997,000) | (247,000) | — | — | — |
| Net loss before income tax expense | (80,765,000) | (56,741,000) | (31,582,000) | (51,944,000) | — | — | — | — |
| Income tax benefit | — | — | 197,000 | — | — | — | — | — |
| Income tax expense | (3,214,000) | (87,000) | — | 284,000 | — | — | — | — |
| Net loss | (83,979,000) | (56,828,000) | (31,385,000) | (51,660,000) | (89,945,000) | (76,849,000) | (36,980,000) | (12,476,000) |
| Other comprehensive loss: | ||||||||
| Foreign currency translation adjustments | — | (3,160) | 2,789 | 248 | 20 | — | — | — |
| Foreign currency translation adjustments | 5,849,000 | — | — | — | — | — | — | — |
| Unrealized gain (loss) on available-for-sale securities | (64,000) | 78,000 | 547,000 | (458,000) | (412,000) | 253,000 | 109,000 | (49,000) |
| Total comprehensive loss | (78,194,000) | (59,910,000) | (28,049,000) | (51,870,000) | (90,337,000) | (76,596,000) | (36,871,000) | (12,525,000) |
| Net loss per share - basic and diluted | — | — | — | — | (3.03) | (2.63) | (1.94) | (3.71) |
| Weighted average shares of common stock outstanding - basic and diluted | — | — | — | — | 29,718,506 | 29,176,232 | 19,031,940 | 3,362,192 |
| Net loss per share - basic (in USD per share) | (1.68) | (1.31) | (0.84) | (1.54) | — | — | — | — |
| Net loss per share - diluted (in USD per share) | (1.68) | (1.31) | (0.84) | (1.54) | — | — | — | — |
| Weighted average shares of common stock outstanding - basic (in shares) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | — | — | — | — |
| Weighted average shares of common stock outstanding - diluted (in shares) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.